Nectar Lifesciences Ltd
NECLIFE
Company Profile
Business description
Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.
Contact
SCO 38-39, Sector 9-D
B-1011/1012, 10th Floor NAURANG HOUSE
Chandigarh160009
INDT: +91 1725047915
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
1,686
Stocks News & Analysis
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
stocks
Insights from reporting season: So far, so good
We’ve upgraded our fair value estimate for 29 companies, or 40% of those that have reported thus far.
stocks
3 cheap ASX stocks owned by top rated funds
Our analysts think these companies are undervalued and their shares appear to have the stamp of approval from highly rated managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,570.90 | 30.80 | -0.36% |
| CAC 40 | 8,154.51 | 31.93 | 0.39% |
| DAX 40 | 22,287.56 | 27.09 | -0.12% |
| Dow JONES (US) | 43,493.51 | 683.14 | -1.55% |
| FTSE 100 | 8,659.37 | 3.60 | -0.04% |
| HKSE | 23,477.92 | 900.94 | 3.99% |
| NASDAQ | 19,644.06 | 318.30 | -1.59% |
| Nikkei 225 | 38,776.94 | 98.90 | 0.26% |
| NZX 50 Index | 12,752.58 | 127.78 | -0.99% |
| S&P 500 | 6,036.09 | 81.43 | -1.33% |
| S&P/ASX 200 | 8,296.20 | 26.60 | -0.32% |
| SSE Composite Index | 3,379.11 | 28.33 | 0.85% |